AACR: new second-line survival data for Opdivo

3 April 2019

Bristol-Myers Squibb (NYSE: BMY) has presented new survival data for Opdivo (nivolumab) at the annual meeting of the American Association for Cancer Research (AACR).

The new pooled analyses consider survival data from four studies, CheckMate -017, -057, -063 and -003, looking at people with advanced non-small cell lung cancer (NSCLC), in the second-line setting.

In the pooled analysis of all four studies, 14% of all Opdivo-treated patients were alive at four years. An analysis of the two Phase III trials, CheckMate -017 and -057, showed the four-year OS rate for the Opdivo group was 14%, compared to 5%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK